291775-59-2 Usage
Description
(3S)-N-Boc-2-azabicyclo[2.2.1]heptane-3-carboxylic acid is a complex carboxylic acid with a bicyclic ring system and a chiral (3S) configuration at the third position. The N-Boc prefix signifies the presence of a tert-butoxycarbonyl protecting group on the nitrogen atom. This unique structure and properties make it a promising candidate for applications in organic synthesis, medicinal chemistry, and material science.
Uses
Used in Organic Synthesis:
(3S)-N-Boc-2-azabicyclo[2.2.1]heptane-3-carboxylic acid is used as a building block or intermediate in the synthesis of various organic compounds. Its unique structure and the presence of the Boc protecting group allow for selective reactions and functional group manipulations, facilitating the synthesis of complex organic molecules.
Used in Medicinal Chemistry:
In the pharmaceutical industry, (3S)-N-Boc-2-azabicyclo[2.2.1]heptane-3-carboxylic acid is used as a key component in the development of new drugs. Its chiral nature and the presence of the Boc protecting group enable the synthesis of enantiomerically pure compounds, which are essential for the biological activity and selectivity of pharmaceutical agents. (3S)-N-Boc-2-azabicyclo[2.2.1]heptane-3-carboxylic acid can be used in the design and synthesis of chiral drugs with improved efficacy and reduced side effects.
Used in Material Science:
(3S)-N-Boc-2-azabicyclo[2.2.1]heptane-3-carboxylic acid can be utilized in the development of novel materials with unique properties. Its complex molecular structure and the presence of the Boc protecting group can be exploited to create new materials with specific characteristics, such as chiral polymers, self-assembling systems, or functionalized surfaces with tailored properties for various applications in material science.
Check Digit Verification of cas no
The CAS Registry Mumber 291775-59-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,9,1,7,7 and 5 respectively; the second part has 2 digits, 5 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 291775-59:
(8*2)+(7*9)+(6*1)+(5*7)+(4*7)+(3*5)+(2*5)+(1*9)=182
182 % 10 = 2
So 291775-59-2 is a valid CAS Registry Number.
291775-59-2Relevant articles and documents
Design, Synthesis and Biological Evaluation of Neogliptin, a Novel 2-Azabicyclo[2.2.1]heptane-Based Inhibitor of Dipeptidyl Peptidase-4 (DPP-4)
Dahlén, Amelia D.,Gureev, Maxim A.,Kirichenko, Olga G.,Maslov, Ivan O.,Porozov, Yuri B.,Schi?th, Helgi B.,Shorshnev, Sergey V.,Trukhan, Mikhail V.,Trukhan, Vladimir M.,Tuaeva, Natalya O.,Zinevich, Tatiana V.
, (2022/03/02)
Compounds that contain (R)-3-amino-4-(2,4,5-trifluorophenyl)butanoic acid substituted with bicyclic amino moiety (2-aza-bicyclo[2.2.1]heptane) were designed using molecular modelling methods, synthesised, and found to be potent DPP-4 (dipeptidyl peptidase-4) inhibitors. Compound 12a (IC50 = 16.8 ± 2.2 nM), named neogliptin, is a more potent DPP-4 inhibitor than vildagliptin and sitagliptin. Neogliptin interacts with key DPP-4 residues in the active site and has pharmacophore parameters similar to vildagliptin and sitagliptin. It was found to have a low cardiotoxic effect compared to sitagliptin, and it is superior to vildagliptin in terms of ADME properties. Moreover, compound 12a is stable in aqueous solutions due to its low intramolecular cyclisation potential. These findings suggest that compound 12a has unique properties and can act as a template for further type 2 diabetes mellitus drug development.
COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS
-
, (2017/03/14)
Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula (I), or a pharmaceutically acceptable salt or composition thereof The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduce the excessive activation of complement.
ETHER COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS
-
, (2017/03/14)
Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an ether substituent (R32) are provided. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduce the excessive activation of complement.
